Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced the appointment of Aaron Ondrey as Chief Financial Officer and made additional key appointments within its leadership team to expand capabilities across the company. These appointments are part of Rocket's preparation for its transition to a commercial stage and the continued development of its genetic therapy pipeline for rare disorders. Aaron Ondrey brings over 20 years of experience in financial management and strategic planning, having previously served as CFO of Mirati Therapeutics and held senior positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals. Other appointments include Kinnari Patel as President and COO, Jonathan Schwartz as Chief Medical & Gene Therapy Officer, Mark White as General Manager of Commercial Affairs, and Martin Wilson as General Counsel & Chief Corporate Officer.